B. Metzler seel. Sohn & Co. AG Has $14.24 Million Position in Boston Scientific Corporation $BSX

Key Points

• B. Metzler seel. Sohn & Co. AG increased its Boston Scientific stake by 25.8% in the second quarter, acquiring 68,450 additional shares. Its position totaled 333,583 shares valued at approximately $14.24 million.
• Analysts maintain a generally positive view, with 24 Buy, five Hold, and two Sell ratings. Boston Scientific has a consensus “Moderate Buy” rating and an average price target of $71.62.
• Boston Scientific recently exceeded quarterly earnings and revenue expectations, while management authorized a $5 billion share-repurchase program. Insider buying totaled about $9.4 million over the past 90 days, including a $9 million purchase by CEO Michael F. Mahoney.

B. Metzler seel. Sohn & Co. AG boosted its holdings in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 25.8% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 333,583 shares of the medical equipment provider's stock after acquiring an additional 68,450 shares during the quarter. B. Metzler seel. Sohn & Co. AG's holdings in Boston Scientific were worth $14,237,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. FWL Investment Management LLC acquired a new position in Boston Scientific during the second quarter worth $26,000. Swiss RE Ltd. acquired a new stake in shares of Boston Scientific in the fourth quarter worth about $26,000. Garton & Associates Financial Advisors LLC acquired a new stake in shares of Boston Scientific in the fourth quarter worth about $26,000. Sfam LLC bought a new stake in shares of Boston Scientific during the 4th quarter worth about $29,000. Finally, Cresta Advisors Ltd. acquired a new position in shares of Boston Scientific during the 4th quarter valued at about $33,000. 89.07% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

BSX has been the topic of a number of recent analyst reports. Wall Street Zen downgraded Boston Scientific from a "buy" rating to a "hold" rating in a research note on Sunday, August 2nd. Argus reiterated a "hold" rating on shares of Boston Scientific in a report on Friday, July 31st. Oppenheimer reduced their target price on shares of Boston Scientific from $90.00 to $85.00 and set an "outperform" rating for the company in a research note on Monday, July 27th. Jefferies Financial Group decreased their target price on shares of Boston Scientific from $100.00 to $67.00 and set a "buy" rating on the stock in a research report on Wednesday, June 24th. Finally, TD Cowen reiterated a "buy" rating and set a $56.00 price objective on shares of Boston Scientific in a research note on Tuesday, August 25th. Twenty-four equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $71.62.

Boston Scientific Stock Performance

Shares of BSX stock opened at $48.40 on Thursday. The company's 50 day moving average price is $46.77 and its two-hundred day moving average price is $55.99. The company has a market capitalization of $70.14 billion, a P/E ratio of 19.59, a price-to-earnings-growth ratio of 1.11 and a beta of 0.57. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.74 and a current ratio of 1.24. Boston Scientific Corporation has a 52 week low of $42.20 and a 52 week high of $109.50.

Boston Scientific (NYSE:BSX - Get Free Report) last released its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, beating analysts' consensus estimates of $0.83 by $0.03. The business had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The firm's revenue for the quarter was up 7.5% compared to the same quarter last year. During the same quarter last year, the firm earned $0.75 earnings per share. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, analysts expect that Boston Scientific Corporation will post 3.3 earnings per share for the current fiscal year.

Boston Scientific declared that its Board of Directors has authorized a share repurchase program on Monday, May 18th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the medical equipment provider to reacquire up to 6.4% of its shares through open market purchases. Shares buyback programs are usually an indication that the company's leadership believes its shares are undervalued.

Insider Activity

In related news, CEO Michael F. Mahoney acquired 186,240 shares of the business's stock in a transaction dated Monday, August 3rd. The stock was bought at an average price of $48.33 per share, with a total value of $9,000,979.20. Following the acquisition, the chief executive officer owned 1,590,024 shares in the company, valued at $76,845,859.92. This represents a 13.27% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director David C. Habiger bought 2,100 shares of the stock in a transaction that occurred on Wednesday, August 5th. The shares were purchased at an average price of $47.59 per share, for a total transaction of $99,939.00. Following the completion of the acquisition, the director owned 17,160 shares of the company's stock, valued at $816,644.40. The trade was a 13.94% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last 90 days, insiders purchased 194,522 shares of company stock valued at $9,385,210. 0.34% of the stock is owned by insiders.

About Boston Scientific

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source